Warning: The NCBI web site requires JavaScript to function. more...
Does higher cost mean better quality? evidence from highly-regarded adolescent drug treatment programs.
Schackman BR, Rojas EG, Gans J, Falco M, Millman RB.
Subst Abuse Treat Prev Policy. 2007 Jul 31;2:23.
Related citations
The quality of highly regarded adolescent substance abuse treatment programs: results of an in-depth national survey.
Brannigan R, Schackman BR, Falco M, Millman RB.
Arch Pediatr Adolesc Med. 2004 Sep;158(9):904-9.
Differential effectiveness of residential versus outpatient aftercare for parolees from prison-based therapeutic community treatment programs.
Burdon WM, Dang J, Prendergast ML, Messina NP, Farabee D.
Subst Abuse Treat Prev Policy. 2007 May 15;2:16.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
An In-Depth Survey of the Screening and Assessment Practices of Highly Regarded Adolescent Substance Abuse Treatment Programs.
Gans J, Falco M, Schackman BR, Winters KC.
J Child Adolesc Subst Abuse. 2010 Jan;19(1):33-47.
Organizational and client determinants of cost in outpatient substance abuse treatment.
Beaston-Blaakman A, Shepard D, Horgan C, Ritter G.
J Ment Health Policy Econ. 2007 Mar;10(1):3-13.
Prevalence and predictors of utilization of community pharmacy generic drug discount programs.
Gatwood J, Tungol A, Truong C, Kucukarslan SN, Erickson SR.
J Manag Care Pharm. 2011 Jul-Aug;17(6):449-55.
Differences in the cost of antidepressants across state Medicaid programs.
Kelton CM, Rebelein RP, Heaton PC, Ferrand Y, Guo JJ.
J Ment Health Policy Econ. 2008 Mar;11(1):33-47.
Costs of day hospital and community residential chemical dependency treatment.
Kaskutas LA, Zavala SK, Parthasarathy S, Witbrodt J.
J Ment Health Policy Econ. 2008 Mar;11(1):27-32.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Diabetes patient education programs. Quality and reimbursement.
Wheeler ML, Warren-Boulton E.
Diabetes Care. 1992 Mar;15 Suppl 1:36-40. Review.
Family income and the impact of a children's health insurance program on reported need for health services and unmet health need.
Feinberg E, Swartz K, Zaslavsky A, Gardner J, Walker DK.
Pediatrics. 2002 Feb;109(2):E29.
Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
French MT, Salomé HJ, Carney M.
Soc Sci Med. 2002 Dec;55(12):2267-82.
Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: a propensity score analysis.
Mojtabai R, Zivin JG.
Health Serv Res. 2003 Feb;38(1 Pt 1):233-59.
Third-party reimbursement coverage for diabetes outpatient education programs.
Tobin CT.
Diabetes Care. 1992 Mar;15 Suppl 1:41-3.
Adolescent-only substance abuse treatment: availability and adoption of components of quality.
Knudsen HK.
J Subst Abuse Treat. 2009 Mar;36(2):195-204. Epub 2008 Nov 11.
Factors that influence staffing of outpatient substance abuse treatment programs.
Lemak CH, Alexander JA.
Psychiatr Serv. 2005 Aug;56(8):934-9.
Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Uldall KK, Ettner SL.
J Ment Health Policy Econ. 2009 Mar;12(1):33-46.
Eligibility for the Medicare buy-in programs, based on a survey of income and program participation simulation.
Rupp K, Sears J.
Soc Secur Bull. 2000;63(3):13-25.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on